PTSM: Pharmaceutical Technology Sourcing and Management, Nov 9, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Nov 9, 2011
Manufacturing
Pfizer Outlines Its Supply Strategy
By Patricia Van Arnum
John Kelly, vice-president of strategy and transitioning sites for Pfizer Global Supply, discusses the company's manufacturing and supply strategy and network.
Global Feature
Contract Manufacturers and Ingredient Suppliers Assemble at CPhI Worldwide.
By Patricia Van Arnum
A roundup of news from fine-chemical suppliers, CDMOs, and CMOs from this year's installment of CPhI Worldwide.
APIs
Technical Perspectives from CPhI Worldwide
By Patricia Van Arnum
Pharmaceutical Technology's podcast series from CPhI.
Outsourcing
Preparing for the Last War
By Jim Miller
CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.
CSR and Sustainability Forum
Energy Conservation in Pharmaceutical Manufacturing
By L. Shamkishore , K. Manmadha Reddy , A. Pathy
The authors discuss opportunities for energy efficiency in pharmaceutical manufacturing.
Pharma Companies Focus on Advancing Women
By Patricia Van Arnum
Pharmaceutical companies join international efforts to reduce maternal and child mortality in the developing world.
CSR and Sustainability in the News
A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other private and public organizations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here